Tests 5-HTP supplement for breathing and anxiety in children with asthma
Tests a supplement, 5-HTP, against a placebo in children with mild or moderate asthma.
Plain-language title generated from the registry record
Registry title: 5HTP Regulation Of Asthma In Children
Key facts
- Where
- Indianapolis, United StatesSee the site
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 8 and 18 years old?
Source: NCT04160910, who can take part
Where in United States
- Indiana UniversityIndianapolis, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Indiana University
- Trial code
- NCT04160910
- Record updated
- 1 October 2026
- Original description
The purpose of this study is to learn more about if taking a supplement called 5-hydroxytryptophan (5HTP) can improve breathing and anxiety symptoms related to asthma. To help learn more subjects will either be assigned to a group that is taking the supplement (5HTP) or a group that is taking a placebo. This will be decided randomly. Later in the study subjects will crossover to the other group.There are 5 study visits over the course of about 12 weeks.Read full original descriptionShow less
5HTP Regulation Of Asthma In Children
The purpose of this study is to learn more about if taking a supplement called 5-hydroxytryptophan (5HTP) can improve breathing and anxiety symptoms related to asthma. To help learn more subjects will either be assigned to a group that is taking the supplement (5HTP) or a group that is taking a placebo. This will be decided randomly. Later in the study subjects will crossover to the other group.There are 5 study visits over the course of about 12 weeks.
Inclusion: Age 8-18 Years of Age; Mild to Moderate Asthma based on ATS guidelines; Positive Allergy Test (positive skin or serum IgE); Weight ≥ 70 lbs (32 kg); CES-DC cut-off ≥ 15 (total score range is 0 to 60) or SCARED cut-off; 25 (total score range is 0 to 142); Ability to comply with study visits and study procedures; Informed Consent by participant and if applicable the parent or legal guardian.
Exclusion: Currently taking a SSRI; Taking a leukotriene inhibitor (montelukast, Zileuton); Taking a biologic medication (omalizumab, mepolizumab, benralizumab, dupilumab); Medical History of Adverse Reaction to 5HTP; Severe Asthma Based on ATS Guidelines; Physical findings that would compromise the safety of the study or the quality of the study data.